Jim Wilson and Tachi Yamada are at it again — launching a 2nd-gen gene therapy company with an appetite for risk, global vision and $200M to gamble with
When Tachi Yamada and Jim Wilson partnered on launching Passage Bio $PASG, the game plan was to use their considerable combined scientific knowhow and global business connections to leap out with new programs for a slate of prospects — therapies that they could be relatively sure of getting through pivotal studies and opening fields for rare CNS diseases. Working with Penn’s Gene Therapy Program, now close to 400 strong on staff, they have a product engine and clinical development plan to get drugs through to the marketplace.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.